3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Suspended
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
18
Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Sarcoma
6
Prostatic Neoplasms
6
Fanconi Anemia, Complementation Group D1
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Mesothelioma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumors
2
Wilms Tumor
1
Interventions
Gemcitabine
79
Cisplatin
56
pembrolizumab
32
Paclitaxel
28
Carboplatin
24
Docetaxel
19
Radiotherapy
17
Mitomycin
16
Doxorubicin
15
atezolizumab
14
BCG Vaccine
14
Nivolumab
13
Cystectomy
13
Filgrastim
11
vinflunine
10
Methotrexate
10
Vinblastine
9
Fluorouracil
9
5-aminolevulinic acid hexyl ester
9
Sunitinib
7
Early Intervention, Educational
7
durvalumab
6
avelumab
6
Taxes
6
Methods
6
Cystoscopy
6
Albumin-Bound Paclitaxel
6
enfortumab vedotin
5
Trastuzumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urinary Bladder Neoplasms
×
olaparib
×
Clear all
NCT03534492
2020-04-06
NEODURVARIB
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
29 enrolled